Peptide Comparison
Thymulin Analog (PAT)vsBPC-157
Synthetic thymulin-derived nonapeptide with potent analgesic and anti-inflammatory properties
The "Wolverine peptide" known for its remarkable healing properties across tendons, ligaments, muscles, and the gut.
At a Glance
Quick
comparison
Dose Range
Thymulin Analog (PAT)
1 mcg–50 mcg mcg
BPC-157
250–500 mcg
Frequency
Thymulin Analog (PAT)
Once daily
BPC-157
Once daily
Administration
Thymulin Analog (PAT)
Intraperitoneal injection
BPC-157
Subcutaneous injection
Cycle Length
Thymulin Analog (PAT)
Ongoing/indefinite
BPC-157
4-6 weeks
Onset Speed
Thymulin Analog (PAT)
Moderate (1-2 weeks)
BPC-157
Moderate (1-2 weeks)
Evidence Level
Thymulin Analog (PAT)
Strong human trials (Phase 3 or FDA approved)
BPC-157
Strong preclinical (extensive animal studies)
Efficacy
Benefit
ratings
Pain Relief
Anti-Inflammatory
Neuroprotection
Primary Benefit
Secondary Benefit
Additional Benefit
Technical Data
Compound
specifications
Thymulin Analog (PAT)
Molecular Formula
C37H62N12O15
Molecular Weight
858.9 Da
Half-Life
Effects peak at 1-2 hours; diminish by 3-4 hours post-single dose
Bioavailability
Effective via intraperitoneal and intracerebroventricular routes in preclinical models
CAS Number
Not assigned
BPC-157
Molecular Formula
C62H98N16O22
Molecular Weight
1419.53 g/mol
Half-Life
4-6 hours
Bioavailability
~100% (subcutaneous)
CAS Number
137525-51-0
Protocols
Dosing
tiers
Thymulin Analog (PAT)
BPC-157
Applications
Best
suited for
Thymulin Analog (PAT)
Neuropathic pain research
Thymulin Analog (PAT) is particularly well-suited for individuals focused on neuropathic pain research. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Anti-inflammatory therapy development
Thymulin Analog (PAT) is particularly well-suited for individuals focused on anti-inflammatory therapy development. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Novel analgesic mechanism investigation
Thymulin Analog (PAT) is particularly well-suited for individuals focused on novel analgesic mechanism investigation. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Cytokine-mediated pain pathway studies
Thymulin Analog (PAT) is particularly well-suited for individuals focused on cytokine-mediated pain pathway studies. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
BPC-157
Tendon and ligament injuries
Sprains, strains, tears, tendinitis - BPC-157 accelerates collagen synthesis and tissue repair
Gut healing
IBS, leaky gut, ulcers, inflammatory bowel conditions - derived from gastric juice, it has a natural affinity for digestive tissue
Muscle injuries
Strains, post-workout recovery, chronic muscle issues - promotes angiogenesis and growth factor expression
Joint problems
Arthritis support, joint pain, cartilage issues - anti-inflammatory and regenerative properties
Post-surgical recovery
Accelerating healing after procedures - works systemically to enhance the body's repair mechanisms
Safety Profile
Side
effects
Thymulin Analog (PAT)
Common
- Injection Site Reaction
- Transient Immune Modulation
- Mild Sedation
- Short Duration of Action
Uncommon
- Potential Immune Suppression
- CNS Effects with Central Administration
Serious
- Unintended Immune Stimulation
BPC-157
Common
- Injection site redness
- Mild nausea
- Dizziness
Uncommon
- Headache
- Fatigue
- Hot/cold sensations
Serious
- Allergic reaction
Research Status
Safety
& evidence
Thymulin Analog (PAT)
Evidence Level
Strong human trials (Phase 3 or FDA approved)
FDA Status
Research compound
Safety Overview
Thymulin Analog (PAT) is a synthetic 9-amino acid peptide (pGlu-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn) that is a research compound ONLY—NOT approved for human use. No serious adverse effects have been documented in extensive preclinical studies spanning 17+ years. However, this is a critical limitation: all data comes from animal models (primarily rats and mice). Zero completed human clinical trials exist. The peptide has not undergone human Phase 1 safety testing. No manufactured batches meet pharmaceutical standards. PAT's primary mechanism—alpha-7 nAChR potentiation—could theoretically affect multiple organ systems, but human safety data is absent. As an immune-modulating compound, prolonged high-dose use could theoretically suppress protective immunity, though animal studies show no adverse effects at therapeutic doses. Individual responses in humans are completely unknown.
Contraindications
- xNot approved for human use
- xPotential immune modulation concerns with chronic use
- xUnknown drug-drug interactions
- xPregnancy and lactation (insufficient safety data)
BPC-157
Evidence Level
Strong preclinical (extensive animal studies)
FDA Status
Research compound
Safety Overview
BPC-157 is a gastric pentadecapeptide with strong preclinical evidence from extensive animal studies spanning over 25 years of research. Critical limitation: BPC-157 has NOT completed Phase 3 human clinical trials. No FDA approval exists. Safety data comes primarily from rat and mouse studies, with only limited Phase 1-2 human data. Animal studies show no toxicity at therapeutic doses, but human data is insufficient for regulatory approval. The peptide is unregulated, and no standardized manufacturing or quality control requirements exist for research compounds. Individual responses may vary significantly, and serious medical supervision is essential before use, particularly if you have gastrointestinal conditions, take medications, or have pre-existing medical conditions.
Contraindications
- xPregnancy
- xBreastfeeding
- xActive cancer
- xHistory of cancer
Decision Guide
Which is
right for you?
Choose Thymulin Analog (PAT) if...
- Neuropathic pain research
- Anti-inflammatory therapy development
- Novel analgesic mechanism investigation
- Cytokine-mediated pain pathway studies
Choose BPC-157 if...
- Injury recovery
- Post-surgery healing
- Chronic pain management
- Gut health